INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Tax withholdingVerified data

Luly Jay R. reported ENTA

Director, President and CEO · ENANTA PHARMACEUTICALS INC · Common Stock

Side
F
Value
$88K
Shares
6,155
Price
$14.25
Executed
Feb 12, 2026
Disclosed
Feb 13, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Feb 12 executedFeb 13, 2026 disclosed

ENTA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+4 / 25

$88K reported value · 0.7% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ENTA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    RT
    Rottinghaus Scott T.Chief Medical Officer
    ENTAENANTA PHARMACEUTICALS INC
    Tax withholding
    		F$20K
    1,467 sh
    		Aug 8, 2026Aug 10, 2026
    traded Aug 8, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HS
    Hata Yujiro SDirector
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    20.0K sh
    		Mar 11, 2026Mar 13, 2026
    traded Mar 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FG
    Foletta Mark GDirector
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    20.0K sh
    		Mar 11, 2026Mar 13, 2026
    traded Mar 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    RL
    Russell LesleyDirector
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    20.0K sh
    		Mar 11, 2026Mar 13, 2026
    traded Mar 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    VT
    Vance TerryDirector
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    20.0K sh
    		Mar 11, 2026Mar 13, 2026
    traded Mar 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Carter Bruce L ADirector
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    20.0K sh
    		Mar 11, 2026Mar 13, 2026
    traded Mar 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PK
    Peterson KristineDirector
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    20.0K sh
    		Mar 11, 2026Mar 13, 2026
    traded Mar 11, 2026
    		+2dSEC FORM 4

    Evidence

    5
    LR
    Luly Jay R.Director, President and CEO
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    15.2K sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KL
    Kieffer Tara LynnChief Product Strategy Officer
    ENTAENANTA PHARMACEUTICALS INC
    Tax withholding
    		F$46K
    3,257 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RT
    Rottinghaus Scott T.Chief Medical Officer
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    1,650 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    13
    RT
    Rottinghaus Scott T.Chief Medical Officer
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    5,225 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RT
    Rottinghaus Scott T.Chief Medical Officer
    ENTAENANTA PHARMACEUTICALS INC
    Tax withholding
    		F$49K
    3,413 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    5
    LB
    Luu BrendanChief Business Officer
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    1,575 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    LB
    Luu BrendanChief Business Officer
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    4,987 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KP
    Kowalsky Matthew PaulChief Legal Officer
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    1,318 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    21
    KP
    Kowalsky Matthew PaulChief Legal Officer
    ENTAENANTA PHARMACEUTICALS INC
    Tax withholding
    		F$27K
    1,902 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    LB
    Luu BrendanChief Business Officer
    ENTAENANTA PHARMACEUTICALS INC
    Tax withholding
    		F$46K
    3,257 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KL
    Kieffer Tara LynnChief Product Strategy Officer
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    1,575 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KL
    Kieffer Tara LynnChief Product Strategy Officer
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    4,987 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    5
    OS
    Or Yat SunChief Scientific Officer
    ENTAENANTA PHARMACEUTICALS INC
    Grant or award
    		A—
    1,650 sh
    		Feb 12, 2026Feb 13, 2026
    traded Feb 12, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002064832-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 12, 2026
    Published
    Feb 13, 2026
    Ingested by INSIDER
    Nov 5, 04:17 UTC
    Last re-read
    Nov 5, 04:17 UTC

    Extracted facts

    Filer
    Luly Jay R.
    Role
    Director, President and CEO
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    ENANTA PHARMACEUTICALS INC
    Ticker
    ENTA
    Shares
    6,155
    Price per share
    $14.25
    Value
    $87,709
    Execution date (reported)
    Feb 12, 2026
    Owned after transaction
    871.9K shares
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 6,155
    • Price: $14.25

    = $87,709

    What this establishes

    Luly Jay R. filed this Form 4 reporting a tax withholding of ENTA on Feb 12, 2026. It became public on Feb 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President and CEO
    Luly Jay R.cik:0001571211
    Issuer
    ENANTA PHARMACEUTICALS INCcik:0001177648

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.